Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Two Insulin Degludec Formulations in Subjects With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes (diagnosed clinically) for minimum 24 weeks prior to randomisation (visit 2)~* Current treatment with basal-only insulin (no prandial insulin) consisting of either insulin detemir once daily (OD), insulin glargine OD or neutral protamine hagedorn (NPH) insulin OD/twice daily (BID) for at least 12 weeks prior to randomisation (visit 2), in combination with stable doses of OAD(s) (metformin, insulin secretagogue (sulfonylurea or glinide), alpha-glucosidase inhibitor, pioglitazone or dipeptidyl peptidase IV (DPP-IV) inhibitor in any approved (according to label) dose or combination. Stable OAD doses are defined as unchanged doses for at least 12 weeks prior to randomisation (visit 2)~* HbA1c (glycosylated haemoglobin) between 7.0-10.0% (both inclusive) by central laboratory analysis~* Body mass index (BMI) below or equal to 45 kg/m\^2~* Ability and willingness to adhere to the protocol including self-measured plasma glucose (SMPG) according to the protocol~Exclusion Criteria:~* Treatment with rosiglitazone within the last 12 weeks prior to randomisation (visit 2)~* Treatment with glucagon like peptide-1 (GLP-1) receptor agonists within the last 12 weeks prior to randomisation (visit 2)~* Recurrent severe hypoglycaemia (more than one severe hypoglycaemic event during the last 12 months) or hypoglycaemic unawareness as judged by the Investigator (trial physician)~* Previous participation in this trial. Participation is defined as randomised. Re-screening is allowed once during the recruitment period~* Known or suspected hypersensitivity to trial products or related products~* The receipt of any investigational drug within 4 weeks prior to randomisation (visit 2)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IDeg 200 U/mL (Type: EXPERIMENTAL): None
- IDeg 100 U/mL (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).